MMC showed no clear difference in failure of functioning trabeculectomy at 1 year compared with 5‐FU (low certainty).
MMC showed no clear difference in loss of 2 or more lines of Snellen visual acuity at 1 year compared with 5‐FU (low certainty).
MMC showed no clear difference in postoperative complications: late hypotony compared with 5‐FU (low certainty).
MMC showed no clear difference in postoperative complications: choroidal detachment compared with 5‐FU (low certainty).
MMC showed no clear difference in postoperative complications: endophthalmitis compared with 5‐FU (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with single‐dose, postoperative MMC‐PD (moderate certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with single‐dose, postoperative MMC‐PD (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with single‐dose, postoperative MMC‐PD (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).